MYDGF
MYDGF (myeloid derived growth factor) is a secreted, bone marrow-derived monocyte and paracrine-acting protein that promotes cardiac myocyte survival and adaptive angiogenesis after myocardial infarction. It was formerly designated IL-25, IL-27 or C19orf10. Browse Assay Genie's current range of MYDGF research reagents below, or read on for the biology behind the target.
MYDGF is a bone marrow-derived monocyte and paracrine-acting protein. UniProt annotates it as promoting cardiac myocyte survival and adaptive angiogenesis, supporting cardiac protection and repair after myocardial infarction (MI). It stimulates endothelial cell proliferation through a MAPK1/3-, STAT3- and CCND1-mediated signalling pathway, and it inhibits cardiac myocyte apoptosis in a PI3K/AKT-dependent pathway. It is also involved more broadly in endothelial cell proliferation and angiogenesis.
The MYDGF gene encodes a protein that belongs to the MYDGF family. The mature MYDGF protein is secreted, and it has also been located to the endoplasmic reticulum, the endoplasmic reticulum-Golgi intermediate compartment and the Golgi apparatus, consistent with passage through the secretory pathway. The mouse ortholog is designated Mydgf.
The naming history of this gene is unusual. The protein was previously thought to support the proliferation of lymphoid cells and was considered an interleukin, which explains the aliases IL-25, IL-27, IL27w and SF20 and the working designation interleukin 27. According to the NCBI Gene summary, that activity has not been reproducible, and the earlier chromosome 19 open reading frame 10 name (C19orf10) reflects its origin as an uncharacterised gene. The same summary states that the function of the protein is currently unknown, whereas the UniProt annotation describes the cardiac and endothelial roles above. Researchers should therefore take care to distinguish MYDGF from the true interleukins that share some of its former names.
MYDGF promotes cardiac myocyte survival and adaptive angiogenesis for cardiac protection and repair following myocardial infarction.
MYDGF is involved in endothelial cell proliferation and angiogenesis, acting through a MAPK1/3-, STAT3- and CCND1-mediated pathway.
MYDGF inhibits cardiac myocyte apoptosis in a PI3K/AKT-dependent signalling pathway, making it relevant to survival signalling studies.
As a bone marrow-derived monocyte and paracrine-acting protein, MYDGF is a candidate for studying monocyte-to-tissue communication.
MYDGF is a paracrine-acting protein from bone marrow-derived monocytes. It promotes cardiac myocyte survival and adaptive angiogenesis after myocardial infarction, stimulates endothelial cell proliferation via MAPK1/3, STAT3 and CCND1, and inhibits cardiac myocyte apoptosis through PI3K/AKT signalling.
The protein was previously thought to support lymphoid cell proliferation and was considered an interleukin. That activity has not been reproducible, so the gene was renamed. The older aliases IL-25, IL-27, IL27w and SF20, and the name C19orf10, are still found in the literature.
A mouse ortholog, Mydgf, is recorded, so rodent models can be used to study this protein. Species suitability varies between reagents, so check the datasheet of any product for its validated reactivity.
Other growth factors, angiogenesis regulators and cardiac signalling markers with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q969H8; product specifications from Assay Genie datasheets.